David F. Fischer

David F. Fischer

Auto-generated profile, based on publicly available information

David F. Fischer

Charles River Nederland BV, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
YWYing-Hui Wu
Ying-Hui Wu
MFMatthijs G. P. Feenstra
Matthijs G. P. Feenstra
JZJiang-Ning Zhou
Jiang-Ning Zhou
RLRong-Yu Liu
Rong-Yu Liu
JTJavier Sastre Toranõ
Javier Sastre Toranõ
DSDick F. Swaab
Dick F. Swaab
A disturbed sleep-wake rhythm is common in Alzheimer disease (AD) patients and correlated with decreased melatonin levels and a disrupted circadian melatonin rhythm. Melatonin levels in the cerebrospinal fluid are decreased during the progression of AD neuropathology (as determined by the Braak stages), already in cognitively intact subjects with the earliest AD neuropathology (Braak stages I-II) (preclinical AD). To investigate the molecular mechanisms behind the decreased melatonin levels, we measured monoamines and mRNA levels of enzymes of the melatonin synthesis and its noradrenergic regulation in pineal glands from 18 controls, 33 preclinical AD subjects, and 25 definite AD patients. Pineal melatonin levels were highly correlated with cerebrospinal fluid melatonin levels. The circadian melatonin rhythm disappeared because of decreased nocturnal melatonin levels in both the preclinical AD and AD patients. Also the circadian rhythm of β1-adrenergic receptor mRNA disappeared in both patient groups. The precursor of melatonin, serotonin was stepwise depleted during the course of AD, as indicated by the up-regulated monoamine oxidase A mRNA and activity (5-hydroxyindoleacetic acid:serotonin ratio). We conclude that a dysfunction of noradrenergic regulation and the depletion of serotonin by increased monoamine oxidase A result in the loss of melatonin rhythm already in preclinical AD.

27 May 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AOA. A. A. M. Danen-Van Oorschot
A. A. A. M. Danen-Van Oorschot
DFD. F. Fischer
D. F. Fischer
JGJ. M. Grimbergen
J. M. Grimbergen
BKB. Klein
B. Klein
SZS.-M. Zhuang
S.-M. Zhuang
MNM. H. M. Noteborn
M. H. M. Noteborn
The chicken anemia virus protein apoptin induces a p53-independent, Bcl-2-insensitive type of apoptosis in various human tumor cells. Here, we show that, in vitro , apoptin fails to induce programmed cell death in normal lymphoid, dermal, epidermal, endothelial, and smooth-muscle cells. However, when normal cells are transformed they become susceptible to apoptosis by apoptin. Long-term expression of apoptin in normal human fibroblasts revealed that apoptin has no toxic or transforming activity in these cells. In normal cells, apoptin was found predominantly in the cytoplasm, whereas in transformed and malignant cells it was located in the nucleus, suggesting that the localization of apoptin is related to its activity. These properties make apoptin a potential agent for the treatment of a large number of tumors, also those lacking p53 and/or overexpressing Bcl-2.

29 April 2002 in Journal of Cell Biology
Verified
Journal Article
Open access
KLKristina Lindsten
Kristina Lindsten
FVFemke M.S. de Vrij
Femke M.S. de Vrij
LVLisette G.G.C. Verhoef
Lisette G.G.C. Verhoef
DFDavid F. Fischer
David F. Fischer
FLFred W. van Leeuwen
Fred W. van Leeuwen
NDNico P. Dantuma
Nico P. Dantuma
Loss of neurons in neurodegenerative diseases is usually preceded by the accumulation of protein deposits that contain components of the ubiquitin/proteasome system. Affected neurons in Alzheimer's disease often accumulate UBB+1, a mutant ubiquitin carrying a 19–amino acid C-terminal extension generated by a transcriptional dinucleotide deletion. Here we show that UBB+1 is a potent inhibitor of ubiquitin-dependent proteolysis in neuronal cells, and that this inhibitory activity correlates with induction of cell cycle arrest. Surprisingly, UBB+1 is recognized as a ubiquitin fusion degradation (UFD) proteasome substrate and ubiquitinated at Lys29 and Lys48. Full blockade of proteolysis requires both ubiquitination sites. Moreover, the inhibitory effect was enhanced by the introduction of multiple UFD signals. Our findings suggest that the inhibitory activity of UBB+1 may be an important determinant of neurotoxicity and contribute to an environment that favors the accumulation of misfolded proteins.

13 February 2009 in Science
Verified
Journal Article
Closed access
PDF file
ATAmantha Thathiah
Amantha Thathiah
KSKurt Spittaels
Kurt Spittaels
MHMarcel Hoffmann
Marcel Hoffmann
MSMik Staes
Mik Staes
ACAdrian Cohen
Adrian Cohen
PMPascal Merchiers
Pascal Merchiers
Deposition of the amyloid-β peptide is a pathological hallmark of Alzheimer's disease. A high-throughput functional genomics screen identified G protein–coupled receptor 3 (GPR3), a constitutively active orphan G protein–coupled receptor, as a modulator of amyloid-β production. Overexpression of GPR3 stimulated amyloid-β production, whereas genetic ablation of GPR3 prevented accumulation of the amyloid-β peptide in vitro and in an Alzheimer's disease mouse model. GPR3 expression led to increased formation and cell-surface localization of the mature γ-secretase complex in the absence of an effect on Notch processing. GPR3 is highly expressed in areas of the normal human brain implicated in Alzheimer's disease and is elevated in the sporadic Alzheimer's disease brain. Thus, GPR3 represents a potential therapeutic target for the treatment of Alzheimer's disease.

24 December 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
XLXiao-Hong Lu
Xiao-Hong Lu
VMVirginia B. Mattis
Virginia B. Mattis
NWNan Wang
Nan Wang
IAIsmael Al-Ramahi
Ismael Al-Ramahi
NBNick van Den Berg
Nick van Den Berg
XYX. William Yang
X. William Yang
Age-related neurodegenerative disorders including Alzheimer’s disease and Huntington’s disease (HD) consistently show elevated DNA damage, but the relevant molecular pathways in disease pathogenesis remain unclear. One attractive gene is that encoding the ataxia-telangiectasia mutated (ATM) protein, a kinase involved in the DNA damage response, apoptosis, and cellular homeostasis. Loss-of-function mutations in both alleles of ATM cause ataxia-telangiectasia in children, but heterozygous mutation carriers are disease-free. Persistently elevated ATM signaling has been demonstrated in Alzheimer’s disease and in mouse models of other neurodegenerative diseases. We show that ATM signaling was consistently elevated in cells derived from HD mice and in brain tissue from HD mice and patients. ATM knockdown protected from toxicities induced by mutant Huntingtin (mHTT) fragments in mammalian cells and in transgenic Drosophila models. By crossing the murine Atm heterozygous null allele onto BACHD mice expressing full-length human mHTT, we show that genetic reduction of Atm gene dosage by one copy ameliorated multiple behavioral deficits and partially improved neuropathology. Small-molecule ATM inhibitors reduced mHTT-induced death of rat striatal neurons and induced pluripotent stem cells derived from HD patients. Our study provides converging genetic and pharmacological evidence that reduction of ATM signaling could ameliorate mHTT toxicity in cellular and animal models of HD, suggesting that ATM may be a useful therapeutic target for HD.

3 July 2006 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
YWYing‐Hui Wu
Ying‐Hui Wu
DFDavid F. Fischer
David F. Fischer
Andries KalsbeekAndries Kalsbeek
Andries Kalsbeek
MGMarie‐Laure Garidou‐Boof
Marie‐Laure Garidou‐Boof
JVJan van der Vliet
Jan van der Vliet
DSDick F. Swaab
Dick F. Swaab
The suprachiasmatic nucleus (SCN) is the “master clock” of the mammalian brain. It coordinates the peripheral clocks in the body, including the pineal clock that receives SCN input via a multisynaptic noradrenergic pathway. Rhythmic pineal melatonin production is disrupted in Alzheimer's disease (AD). Here we show that the clock genes hBmal1, hCry1 , and hPer1 were rhythmically expressed in the pineal of controls (Braak 0). Moreover, hPer1 and h β 1‐adrenergic receptor ( h β 1‐ADR ) mRNA were positively correlated and showed a similar daily pattern. In contrast, in both preclinical (Braak I‐II) and clinical AD patients (Braak V‐VI), the rhythmic expression of clock genes was lost as well as the correlation between hPer1 and h β 1‐ADR mRNA. Intriguingly, hCry1 mRNA was increased in clinical AD. These changes are probably due to a disruption of the SCN control, as they were mirrored in the rat pineal deprived of SCN control. Indeed, a functional disruption of the SCN was observed from the earliest AD stages onward, as shown by decreased vasopressin mRNA, a clock‐controlled major output of the SCN. Thus, a functional disconnection between the SCN and the pineal from the earliest AD stage onward could account for the pineal clock gene changes and underlie the circadian rhythm disturbances in AD.—Wu, Y‐H., Fischer, D. F., Kalsbeek, A., Garidou‐Boof, M‐L., van der Vliet, J., van Heijningen, C., Liu, R‐Y., Zhou, J‐N., Swaab, D. F. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the “master clock.” FASEB J . 20, E1171–E1180 (2006)